Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that the activation phase on day 28 of the Chaperone Rich Cell Lysate (CRCL)-AlloVaxTM protocol is designed to awaken the memory type 1 T-helper cells (Th1 cells) and cytotoxic T lymphocyte (CTL) killer cells that were formed during the earlier priming and vaccination phases of the study protocol. These new Th1 and CTL cells are known as adaptive immune cells. Dr. Michael Har-Noy goes on to say that the activation phase of the study enables these adaptive immune cells to exit the circulation and travel to the sites of the patient's tumor. Additionally, the activation phase of the protocol conditions the microenvironment of the malignant tumor to facilitate immune-mediated tumor killing by both the adaptive immune Th1 and CTL cells as well as by the patient's innate natural killer cells and macrophages. Furthermore, says Dr. Michael Har-Noy, this phase is designed to disable the tumor's ability to escape attack by the patient's immune system. Dr. Michael Har-Noy points out that the combination of these mechanisms is what renders the CRCL-AlloStim™ anti-tumor vaccine unique among all other tumor vaccines and treatments.
The unique characteristics of AlloStim™, says Dr. Michael Har-Noy, permit all these diverse immune mechanisms to occur together. An intravenous infusion of AlloStim™ is given to the study patient on day 28 of the protocol in order to engage and maximize the full potential of the compound's special properties. Dr. Michael Har-Noy says that the AlloStim™ cells are suspended in five milliliters of formulation media, and are then slowly infused over a five to ten minute period. The study patient's vital signs are continuously monitored during the infusion and for at least two hours afterward in order to monitor for any adverse effects or reactions. Dr. Michael Har-Noy says that the most common side effect of the infusion is a syndrome of flu-like symptoms four to 24 hours after the AlloStimTM administration. These symptoms, which include fever, chills and sweating, usually subside within the first 48 hours after the infusion.
Readers should visit www.immunocare.net for further information about Dr. Michael Har-Noy's phase I/II CRCL-AlloVaxTM protocol and his Compassionate Use program in Bangkok, Thailand.